Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HROW Harrow	$35.89 -0.7%	$29.90	$20.85 ▼ $59.23	$1.32B	0.41	499,637 shs	481,718 shs
NTLA Intellia Therapeutics	$12.06 +1.9%	$9.38	$5.90 ▼ $27.77	$1.25B	2.21	3.06 million shs	3.83 million shs
TNXP Tonix Pharmaceuticals	$46.91 -0.6%	$34.63	$6.76 ▼ $130.00	$345.26M	2.05	996,077 shs	1.47 million shs
WVE WAVE Life Sciences	$8.34 +4.1%	$6.79	$5.04 ▼ $16.74	$1.30B	-1.01	1.33 million shs	2.46 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HROW Harrow	+4.60%	+15.21%	+18.84%	+50.65%	+43.70%
NTLA Intellia Therapeutics	-1.09%	-2.71%	+23.49%	+63.62%	-56.76%
TNXP Tonix Pharmaceuticals	+4.73%	+11.40%	+35.14%	+200.38%	-20.82%
WVE WAVE Life Sciences	+2.43%	+0.75%	+21.55%	+35.30%	+35.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HROW Harrow	2.3836 of 5 stars	3.5	1.0	0.0	2.4	2.5	0.6
NTLA Intellia Therapeutics	4.4215 of 5 stars	4.3	1.0	4.7	1.9	2.5	0.6
TNXP Tonix Pharmaceuticals	2.5985 of 5 stars	3.5	2.0	0.0	1.3	3.3	0.6
WVE WAVE Life Sciences	4.5306 of 5 stars	3.5	2.0	4.8	2.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HROW Harrow	3.00	Buy	$63.83	76.70% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	173.40% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,163.50% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.15	151.11% Upside

Current Analyst Ratings Breakdown

Latest TNXP, HROW, NTLA, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/11/2025	HROW Harrow	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$76.00
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/12/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$62.00
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
6/10/2025	HROW Harrow	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HROW Harrow	$199.61M	6.64	$0.14 per share	252.67	$1.95 per share	18.53
NTLA Intellia Therapeutics	$57.88M	21.84	N/A	N/A	$8.56 per share	1.43
TNXP Tonix Pharmaceuticals	$10.09M	33.77	N/A	N/A	$31.82 per share	1.46
WVE WAVE Life Sciences	$108.30M	11.53	N/A	N/A	$1.37 per share	5.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HROW Harrow	-$17.48M	-$0.56	N/A	90.31	N/A	-10.19%	-25.01%	-4.27%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/14/2025 (Estimated)

Latest TNXP, HROW, NTLA, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$6.71	N/A	N/A	N/A	$2.60 million	N/A
8/14/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	N/A	N/A	N/A	$12.26 million	N/A
8/14/2025	Q2 2025	WVE WAVE Life Sciences	-$0.28	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	HROW Harrow	$0.01	N/A	N/A	N/A	$64.23 million	N/A
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million
5/8/2025	Q1 2025	HROW Harrow	$0.02	-$0.38	-$0.40	-$0.50	$57.00 million	$47.83 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HROW Harrow	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HROW Harrow	2.01	0.91	0.85
NTLA Intellia Therapeutics	N/A	4.90	4.90
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HROW Harrow	72.76%
NTLA Intellia Therapeutics	88.77%
TNXP Tonix Pharmaceuticals	82.26%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
HROW Harrow	15.16%
NTLA Intellia Therapeutics	3.10%
TNXP Tonix Pharmaceuticals	0.03%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HROW Harrow	180	36.69 million	31.12 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

TNXP, HROW, NTLA, and WVE Headlines

Recent News About These Companies

Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views

July 16 at 6:40 PM | benzinga.com

Citigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy Recommendation

July 16 at 6:40 PM | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Should You Buy?

July 16 at 10:59 AM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Coverage Initiated at Citigroup

July 16 at 8:37 AM | marketbeat.com

Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions

July 15 at 12:03 AM | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?

July 15 at 4:23 PM | marketbeat.com

Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24

July 11, 2025 | msn.com

NASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.com

July 11, 2025 | investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?

July 9, 2025 | marketbeat.com

Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50

July 9, 2025 | americanbankingnews.com

WAVE Life Sciences Ltd. Company & People | WVE | Barron's

July 7, 2025 | barrons.com

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

July 7, 2025 | seekingalpha.com

Wave Life Sciences: Speculative, But Promising

July 7, 2025 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) - Yahoo Finance

July 6, 2025 | finance.yahoo.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages

July 6, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Moody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 4, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

July 3, 2025 | msn.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
By Brian O'Connell | July 15, 2025
View Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

TNXP, HROW, NTLA, and WVE Company Descriptions

Harrow NASDAQ:HROW

$35.89 -0.25 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$36.04 +0.16 (+0.43%)

As of 04:19 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Intellia Therapeutics NASDAQ:NTLA

$12.06 +0.23 (+1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$12.06 0.00 (0.00%)

As of 04:39 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Tonix Pharmaceuticals NASDAQ:TNXP

$46.91 -0.28 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$46.95 +0.04 (+0.09%)

As of 04:39 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

WAVE Life Sciences NASDAQ:WVE

$8.34 +0.33 (+4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.64 +0.30 (+3.59%)

As of 04:13 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time